Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Global Health Limited (GLH.AX)
Melbourne, VIC, AU
Headquartered in Melbourne, Australia, and established in 1985, Global Health Limited develops and supplies digital health solutions for the Australian healthcare sector. Their comprehensive suite of software addresses various needs, including specialized platforms for mental health practitioners like psychologists and psychiatrists. The company provides integrated solutions across community health and human services, encompassing areas such as drug and alcohol support, disability services, post-acute and community care, and rehabilitation. Furthermore, they offer solutions for home and aged care, general practice, pharmacies, and consumer engagement. Key products include the MasterCare Electronic Medical Record (EMR), MasterCare + for digitizing services, and MasterCare Patient Administration System (PAS). PrimaryClinic provides medical and practice management capabilities for GPs and specialists, enabling shared patient demographic data. Other significant tools are ReferralNet for secure document exchange, LifeCard as a personal health record, and HotHealth for digital patient engagement. Complementing these are the MasterCare Data Warehouse for streamlined data analysis, e-switch middleware for seamless system integration, a Patient Portal for digital pre-admission data capture, and Altitude, their cloud hosting service.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.64% | +1.64% | -13.89% | -13.89% | -31.87% | -27.06% | -21.52% | -60.00% | -90.39% | -85.49% | -98.84% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-01 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+6.7% Q4'25: -11.0% (vs Q4'23)
-
EPS growth Medical - Care Facilities: +19.2%+34.1% ★ Q4'25: +45.1% (vs Q4'23)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+0.9% Q4'25: -2.4% (vs Q4'23)
-
EBIT margin Medical - Care Facilities: +11.3%-9.3% Q4'25: -26.3% (vs Q4'23)
-
ROIC Medical - Care Facilities: +6.8%— Q4'25: +100.7% (vs Q4'23)
-
Share dilution Medical - Care Facilities: +0.0%+0.3% Q4'25: +1.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×-1.84× Q4'25: -0.43× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|
| Revenue |
8.67M
est: 705.12M (-98.8%)
|
833.15M
833.15M – 833.15M
+18.2% YoY
|
| EBITDA |
-793.1K
est: -208.74M (+99.6%)
|
-246.64M
-246.64M – -246.64M
-18.2% YoY
|
| EBIT |
-801.8K
est: -236.45M (+99.7%)
|
-279.38M
-279.38M – -279.38M
-18.2% YoY
|
| Net Income |
-866.6K
est: 21.65M (-104.0%)
|
26.72M
26.72M – 26.72M
+23.4% YoY
|
| SGA |
795.1K
est: 104.30M (-99.2%)
|
123.24M
123.24M – 123.24M
+18.2% YoY
|
| EPS |
-0.01
est: 0.37 (-104.0%)
|
0.46
0.46 – 0.46
+23.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alumootil Mathew Ravi Cherian MACS | Group MD & Executive Director | 336.1K | male |
| Damon Groenveld | Chief Technology Officer | 255.7K | male |
| Chris Fernandes | Joint Company Secretary | — | male |
| Anara Malabekova | Joint Company Secretary & Group Financial Controller | — | female |
| Eryl Baron AGIA | Company Secretary | — | female |
| Gareth Hooper | Chief Information Officer | — | male |
| Jessica Moore | Vice President of Investor Relations | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GLH.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
